IAIS 2023 5th Annual Indiana Allergy Meeting
The Indiana Allergy and Immunology Society's 5th Annual Meeting will feature nationally recognized speakers presenting on diverse topics within the field of Allergy and Immunology. There will also be 2 Fellows presentations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Indiana Allergy and Immunology Society (IAIS). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary care physicians
Allied healthcare professionals
At the conclusion of this meeting, learners should be able to…
1. Organize a treatment plan for a patient with drug hypersensitivity.
2. Collect data on how to become involved in local, state and national associations and organize ways to make changes for our patients and our profession.
3. Summarize differences in treating pediatric and adult drug hypersensitivity.
4. Construct a plan for patients with PID, understanding the need to refer, when appropriate.
5. Critique fellows’ case presentations of unique cases at Indiana University.
Indiana Allergy and Immunology Society
5th Annual Conference
September 30, 2023
7:00 AM – 8:00 AM Breakfast/Registration/Networking
8:00 AM – 9:00 AM Dr. Anna Wolfson – Drug Allergy:Beyond the Basics
9:00 AM – 10:00 AM Dr. Mahboobeh Mahdavinia – Nasal and gut microbiome in allergic diseases
10:00 AM – 10:30 AM Coffee Break/Exhibit Hall
10:30 AM – 11:30 AM Allergy & Immunology Fellow Presentations
An Huyn, MD - Mycobacteria and Immune Deficiency
Jillian Belmonte, MD - Eosinophilia in a Patient on Dupilumab Associated with Multiple Parasite Infections
11:30 AM – 12:45 PM Lunch
Annual Business Meeting/Exhibit Hall/Networking
12:45 PM – 1:45 PM Dr. Mercy Hylton – How to become involved with local advocacy efforts that impact our practice
1:45 PM – 2:45 PM Dr. Nurcicek Padem – Inborn Errors of Immunity
2:45 PM – 2:55 PM Closing Remarks and Adjourn
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All relevant financial relationships with ineligible companies have been mitigated.
Kirsten Kloepfer, MD, Planner
Mahboobeh Mahdavinia, MD, PhD, speaker
The following individuals have no relevant financial relationships with ineligible companies to disclose:
Leena Padhye, MD, planner
Anna Wolfson, MD, speaker
Mercy Hylton, MD, speaker
Nuricek Padem, MD, speaker
An Huynh, MD, speaker
Jillian Belmonte, MD, speaker
- 5.00 AMA PRA Category 1 Credit™
- 5.00 Attendance